Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Expert Rev Hematol ; 12(10): 801-808, 2019 10.
Article in English | MEDLINE | ID: mdl-31432732

ABSTRACT

Introduction: Outcomes of patients with classical Hodgkin lymphoma are excellent, and the intent of frontline therapy for even advanced-stage disease has been curative. This review summarizes the role of brentuximab vedotin in the upfront treatment of advanced stage classical Hodgkin lymphoma in the context of reducing therapy-related toxicity without compromising the high cure rate. Areas covered: Strategies to reduce bleomycin-induced lung toxicity include a response-adapted approach investigated in the RATHL study and a replacement of bleomycin with brentuximab vedotin in frontline chemotherapy regimens. In both studies, omission of bleomycin in the non-standard arms decreased the rate of pulmonary toxicity while maintaining high progression-free survival and overall survival rates. Expert opinion: The approval of A+AVD in North America offers a new bleomycin-free regimen for the treatment of advanced-stage HL, but it must be balanced against a risk-adapted approach. Recently presented subset analyses raise a question about which patients benefit most from this therapy.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bleomycin/administration & dosage , Brentuximab Vedotin/therapeutic use , Hodgkin Disease/drug therapy , Immunotoxins/therapeutic use , Antineoplastic Agents, Immunological/economics , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bleomycin/adverse effects , Bleomycin/economics , Brentuximab Vedotin/economics , Clinical Trials as Topic , Cost-Benefit Analysis , Dacarbazine/economics , Dacarbazine/therapeutic use , Doxorubicin/economics , Doxorubicin/therapeutic use , Female , Hodgkin Disease/diagnosis , Hodgkin Disease/economics , Hodgkin Disease/mortality , Humans , Immunotoxins/economics , Male , Middle Aged , Neoplasm Staging , Practice Guidelines as Topic , Survival Analysis , Vinblastine/economics , Vinblastine/therapeutic use
3.
MAbs ; 1(3): 281-7, 2009.
Article in English | MEDLINE | ID: mdl-20065645

ABSTRACT

Full-length antibodies and antibodies that ferry a cargo to target cells are desired biopharmaceuticals. We describe the production of full-length IgGs and IgG-toxin fusion proteins in E. coli. In the presented examples of anti CD30 and anti EGF-receptor antibodies, the antibody heavy and light chains or toxin fusions thereof were expressed in separate bacterial cultures, where they accumulated as insoluble inclusion bodies. Following refolding and purification, high yields (up to 50 mg/L of shake flask culture) of highly purified (>90%) full-length antibodies and antibody-toxin fusions were obtained. The bacterially produced antibodies, named "Inclonals," equaled the performance of the same IgGs that were produced using conventional mammalian cell culture in binding properties as well as in cell killing potency. The rapid and cost effective IgG production process and the high quality of the resultant product may make the bacterial production of full-length IgG and IgG-drug fusion proteins an attractive option for antibody production and a significant contribution to recombinant antibody technology.


Subject(s)
Escherichia coli/genetics , Immunoglobulin G/metabolism , Immunotoxins/metabolism , Recombinant Fusion Proteins/metabolism , Animals , Antibody-Dependent Cell Cytotoxicity , Cost-Benefit Analysis , ErbB Receptors/immunology , Gene Expression/genetics , Gene Expression/immunology , Humans , Immunoglobulin G/economics , Immunoglobulin G/genetics , Immunoglobulin G/immunology , Immunotoxins/economics , Immunotoxins/genetics , Immunotoxins/immunology , Inclusion Bodies/immunology , Inclusion Bodies/microbiology , Ki-1 Antigen/immunology , Protein Binding , Protein Folding , Recombinant Fusion Proteins/economics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...